- President von der Leyen announced that the EU has achieved its goal of fully vaccinating 70% of its adult population on 31 August
- The EU and AstraZeneca agree on COVID-19 vaccine supply and on ending litigation
- Commission approves new contract for a potential COVID-19 vaccine with Novavax
- EU makes available additional humanitarian funding of €41 million to fight the pandemic
- EMA starts rolling review of COVID-19 vaccine Vidprevtyn
Figures on vaccination
- 738.6 million doses delivered
- 73.4 %of the EU adult population fully vaccinated
Last updated: 21 September 2021. Source: Vaccines producers and ECDC data.
31 August 2021 - 70% of the EU adult population fully vaccinated against COVID-19
The EU has reached a crucial milestone with 70% of the adult population now fully vaccinated against COVID-19. In total, over 256 million adults in the EU have now received a full vaccine course. Seven weeks ago, the Commission’s delivery target was met ahead of time: to provide Member States with enough vaccine doses by the end of July to fully vaccinate 70% of the adult EU population.
Information about vaccination in the EU
Securing doses of future vaccines
The European Commission has been negotiating intensely to build a diversified portfolio of vaccines for EU citizens at fair prices. Contracts have been concluded with 7 promising vaccine developers, securing a portfolio of up to 4.6 billion doses.
Deliveries of vaccine doses to European Union countries have increased steadily since December. Vaccination gathers pace across the European Union.
The Commission has so far given 4 conditional marketing authorisations for the vaccines developed by BioNTech and Pfizer, Moderna, AstraZeneca and Janssen Pharmaceutica NV following EMA positive assessment of their safety and efficacy. Several other vaccines are at different stages of assessment by the European Medicines Agency (EMA).
The Commission is working closely with the industry to step up vaccine manufacturing capacity in the EU.
At the same time, the Commission has started work to anticipate and tackle new variants of the virus and to rapidly develop and produce on a large-scale vaccines effective against those variants.
This is why the European Commission has launched the HERA Incubator. It will bring together science, industry and public authorities, to speed up work and leverage all available resources to enable Europe to respond to this threat.
- up to 4.6 billion doses
Type of vaccine
Number of doses
(needed per person)
Number of doses
|BioNTech and Pfizer||mRNA||2 doses||2.4 billion*||Approved|
|Moderna||mRNA||2 doses||460 million||Approved|
|CureVac||mRNA||2 doses||405 million||Under EMA rolling review|
|AstraZeneca||adenovirus||2 doses||400 million||Approved|
|Johnson & Johnson/Janssen Pharmaceuticals||adenovirus||1 dose||400 million||Approved|
|Sanofi-GSK||protein||2 doses||300 million||Under EMA rolling review|
|Novavax||protein||2 doses||200 million**||Under EMA rolling review|
*option to purchase 900 million doses, **option to purchase 100 million doses
The Commission has also concluded exploratory talks with
- Valneva with a view to purchase up to 60 million doses.
The European Medicines Agency publishes safety updates for the COVID-19 vaccines authorised in the EU. EMA releases a monthly update for each authorised COVID-19 vaccine.
The safety updates summarise the data that have become available since the vaccine's authorisation. They also indicate whether any safety information requires further investigation.
For more information, visit the EMA webpage.
Check the facts
Disinformation on the coronavirus is thriving. It is important that you get updated information from authoritative sources only. We suggest that you follow the advice of your public health authorities, and the websites of relevant EU and international organisations: the European Centre for Disease Control (ECDC ) and the World Health Organisation (WHO).
You can also help by not sharing unverified information that comes from dubious sources.
The EU vaccine strategy
With the EU Vaccines Strategy, the EU is supporting efforts to accelerate the development and availability of safe and effective vaccines in a timeframe between 12 and 18 months, if not earlier. Delivering on this complex task requires running clinical trials in parallel with investing in production capacity to be able to produce millions, or even billions, of doses of a successful vaccine.
Interview about vaccination with Ms Marie-Francoise Fuchs
How do vaccines work?